Biond Biologics Taps Giovanni Selvaggi to Lead Clinical Strategy

Dr. Selvaggi arrives from Xcovery Holdings, where he directed the global Phase 3 clinical program for ensartinib and managed regulatory navigation with the U.S. Food and Drug Administration. His background includes significant tenures at Bristol Myers Squibb, where he contributed to the regulatory filing of nivolumab, as well as senior roles at Novartis Oncology and GlaxoSmithKline. A pulmonologist by training, he previously spent ten years treating patients and conducting research at Italy’s University of Turin and San Luigi Hospital.

His arrival coincides with a pivotal period for Biond, which currently manages two distinct clinical-stage assets. The company is progressing BND-22, a multi-cell checkpoint inhibitor targeting the ILT2 receptor, through Phase 2 trials. Simultaneously, the firm is initiating human studies for BND-67, a therapy designed to restore physiological CD28 signaling. By preventing CD28 shedding, the drug aims to preserve T-cell activation while suppressing regulatory T-cell function. CEO Tehila Ben Moshe noted that Selvaggi’s expertise in navigating early clinical development through to regulatory submission will be vital as the company seeks to unlock the potential of its first-in-class portfolio.